AQST
Income statement / Annual
Last year (2023), Aquestive Therapeutics, Inc.'s total revenue was $50.58 M,
an increase of 6.09% from the previous year.
In 2023, Aquestive Therapeutics, Inc.'s net income was -$7.87 M.
See Aquestive Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$50.58 M
|
$47.68 M
|
$50.83 M
|
$45.85 M
|
$52.61 M
|
$67.43 M
|
$66.92 M
|
$51.79 M
|
| Cost of Revenue |
$20.83 M |
$19.39 M |
$14.99 M |
$12.96 M |
$20.36 M |
$20.99 M |
$19.82 M |
$16.38 M |
| Gross Profit |
$29.75 M |
$28.29 M |
$35.84 M |
$32.89 M |
$32.25 M |
$46.44 M |
$47.10 M |
$35.41 M |
| Gross Profit Ratio |
0.59 |
0.59 |
0.71 |
0.72 |
0.61 |
0.69 |
0.7 |
0.68 |
| Research and Development
Expenses |
$13.10 M
|
$17.48 M
|
$17.05 M
|
$19.89 M
|
$20.57 M
|
$23.11 M
|
$22.13 M
|
$15.45 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$72.26 M
|
$25.08 M
|
$20.80 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$31.75 M
|
$52.88 M
|
$53.48 M
|
$55.89 M
|
$64.34 M
|
$72.26 M
|
$25.08 M
|
$20.80 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$5,000.00 |
$0.00 |
-$99,000.00 |
| Operating Expenses |
$44.85 M |
$70.36 M |
$70.52 M |
$75.78 M |
$84.92 M |
$95.38 M |
$47.21 M |
$36.25 M |
| Cost And Expenses |
$65.69 M |
$89.75 M |
$85.51 M |
$88.74 M |
$105.28 M |
$116.36 M |
$67.03 M |
$52.63 M |
| Interest Income |
$16.32 M |
$99,000.00 |
$423,000.00 |
$132,000.00 |
$636,000.00 |
$552,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$7.46 M |
$12.44 M |
$22.46 M |
$13.02 M |
$9.32 M |
$7.71 M |
$7.71 M |
$6.14 M |
| Depreciation &
Amortization |
$1.35 M
|
$2.39 M
|
$2.96 M
|
$3.61 M
|
$3.05 M
|
$3.34 M
|
$3.80 M
|
$3.89 M
|
| EBITDA |
$1.18 M
|
-$39.58 M
|
-$45.11 M
|
-$39.15 M
|
-$53.88 M
|
-$50.33 M
|
$2.57 M
|
$2.95 M
|
| EBITDA Ratio |
0.02 |
-0.88 |
-0.67 |
-0.93 |
-0.99 |
-0.72 |
0.06 |
0.06 |
| Operating Income Ratio
|
-0.3
|
-0.88
|
-0.68
|
-0.94
|
-1
|
-0.73
|
-0
|
-0.02
|
| Total Other
Income/Expenses Net |
$7.48 M
|
-$12.34 M
|
-$35.86 M
|
-$12.89 M
|
-$13.58 M
|
-$12.44 M
|
-$8.83 M
|
-$8.76 M
|
| Income Before Tax |
-$7.63 M |
-$54.41 M |
-$70.54 M |
-$55.78 M |
-$66.25 M |
-$61.38 M |
-$8.94 M |
-$9.60 M |
| Income Before Tax Ratio
|
-0.15
|
-1.14
|
-1.39
|
-1.22
|
-1.26
|
-0.91
|
-0.13
|
-0.19
|
| Income Tax Expense |
$245,000.00 |
$5.79 M |
$19.50 M |
$9.58 M |
$6.41 M |
-$4.73 M |
$7.71 M |
$6.04 M |
| Net Income |
-$7.87 M |
-$60.20 M |
-$90.04 M |
-$65.36 M |
-$72.66 M |
-$61.38 M |
-$8.94 M |
-$9.60 M |
| Net Income Ratio |
-0.16 |
-1.26 |
-1.77 |
-1.43 |
-1.38 |
-0.91 |
-0.13 |
-0.19 |
| EPS |
-0.13 |
-1.24 |
-2.36 |
-1.94 |
-2.87 |
-2.96 |
-0.45 |
-0.39 |
| EPS Diluted |
-0.13 |
-1.24 |
-2.36 |
-1.94 |
-2.87 |
-2.96 |
-0.45 |
-0.39 |
| Weighted Average Shares
Out |
$61.26 M
|
$48.73 M
|
$38.08 M
|
$33.65 M
|
$25.36 M
|
$20.73 M
|
$20.00 M
|
$24.50 M
|
| Weighted Average Shares
Out Diluted |
$61.26 M
|
$48.73 M
|
$38.08 M
|
$33.65 M
|
$25.36 M
|
$20.73 M
|
$20.00 M
|
$24.50 M
|
| Link |
|
|
|
|
|
|
|
|
